Temozolomide: a novel treatment for pituitary carcinoma

Lancet Oncology

Volumn 7, Issue 6, 2006, Pages 518-520

  Lim, Stephen ^a   Shahinian, Hrayr ^b   Maya, Menahem M ^a   Yong, William ^a   Heaney, Anthony P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; GLUCOCORTICOID; PROLACTIN; TEMOZOLOMIDE; THYROID HORMONE;

AGED; ARTICLE; CANCER INVASION; CASE REPORT; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; DYSPHAGIA; FACIAL NERVE PARALYSIS; HEADACHE; HUMAN; HYPOPHYSIS APOPLEXY; HYPOPHYSIS CARCINOMA; HYPOPHYSIS TUMOR; HYPOPITUITARISM; IMMUNOPATHOLOGY; MALE; MITOSIS; NAUSEA; NOSE DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESYNCOPE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA; COMBINED MODALITY THERAPY; DACARBAZINE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PITUITARY NEOPLASMS; TREATMENT OUTCOME;

EID: 33744501578     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70728-8     Document Type: Article

References (10)

1. Sellman W., Laws E., Scheithauer B., and Carpenter S. The occurrence of dural invasion in pituitary adenomas. J Neurosurgery 64 (1986) 402-407
2. Kaltsas G., Nomikos P., Kontogeorgos G., et al. Diagnosis and management of pituitary carcinoma. J Clin Endocrinol Metab 90 (2005) 3089-3099
3. Ragel B., and Couldwell W. Pituitary carcinoma: a review of the literature. Neurosurg Focus 16 (2004) E7
4. Thapar K., Scheithauer B., Kovacs K., et al. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38 (1996) 763-771
5. Heaney A., and Melmed S. Pituitary tumors: molecular targets and new medical therapies. Nat Rev Cancer 4 (2004) 285-295
6. Minniti G., Traish D., Ashley S., et al. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 90 (2005) 800-804
7. Laws Jr. E., Morris A., and Maartens N. Gliadel for pituitary adenomas and craniopharyngiomas. Neurosurgery 53 (2003) 255-269
8. De angelis L. Brain tumors. N Engl J Med 344 (2001) 114-123
9. Stupp R., Mason W., van den Bent M., et al., European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 10 352 (2005) 987-996
10. Gillam M., Middler S., Freed D., and Molitch M. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 87 (2002) 4447-4451